Ascendis Pharma

ASNDApproved

Ascendis Pharma applies its TransCon transient conjugation technology to transform established drugs into long-acting therapies with improved dosing convenience and potentially enhanced efficacy. The company has a robust pipeline in endocrinology rare diseases and oncology, with several Phase 2 and Phase 3 trials ongoing. With headquarters in Denmark and operations across Europe and the US, Ascendis has established partnerships in China and Japan to expand global reach of its innovative therapies.

Market Cap

$13.6B

Focus

Biologics

ASND · Stock Price

USD 221.88+107.49 (+93.97%)

Historical price data

AI Company Overview

Technology Platform

TransCon (transient conjugation) technology platform that temporarily links inert carriers to parent drugs, enabling predictable release of unmodified active compounds with extended dosing intervals from daily to up to six months.

Pipeline Snapshot

25 drugs in pipeline, 8 in Phase 3

Drug	Indication	Stage
Lonapegsomatropin + Somatropin	Growth Hormone Deficiency	Phase 3
Lonapegsomatropin	Adult Growth Hormone Deficiency	Phase 3
TransCon hGH	Growth Hormone Deficiency, Pediatric	Phase 3
TransCon hGH	Growth Hormone Deficiency, Pediatric	Phase 3
TransCon hGH + daily hGH	Growth Hormone Deficiency	Phase 3

Funding History

Total raised: $200M

IPO$100MUndisclosedJan 30, 2015

Series C$50MRA Capital ManagementJun 15, 2013

Series B$30MNovo A/SJun 15, 2010

Series A$20MNovo A/SJun 15, 2007

FDA Approved Drugs

YORVIPATHNDAAug 9, 2024

SKYTROFABLAAug 25, 2021

Opportunities

Multiple Phase 3 and pivotal trials offer near-term value catalysts, while the TransCon platform provides opportunities for expansion into additional therapeutic areas and geographic markets through partnerships.

The rare disease focus provides potential for premium pricing and orphan drug incentives.

Risk Factors

Clinical development risks across multiple mid-stage programs, increasing competition in long-acting therapeutics, and potential manufacturing complexities associated with the TransCon platform technology.

Regulatory approval timelines may be extended for complex rare disease indications.

Competitive Landscape

Ascendis competes in the long-acting therapeutics space against established pharma and emerging biotechs, differentiated by its proprietary TransCon platform and focus on established drug mechanisms with proven biology. The company's multi-indication approach and global partnership strategy provide competitive advantages in rare disease markets.

Publications

Patents

Pipeline

FDA Approvals